Benfotiamine in Diabetic Nephropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effect of benfotiamine supplementation in patients with diabetic nephropathy, and to determine whether it will slow down the progression to end-stage renal disease (ESRD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

NCT00930865

Type 2 Diabetes Mellitus

COMPLETED PHASE1

Niclosamide Role in Diabetic Nephropathy

NCT04317430

Diabetic Nephropathies

COMPLETED PHASE3

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

NCT04929379

Diabetic Nephropathies

ACTIVE_NOT_RECRUITING PHASE2

Effects of PH3 in Diabetic Nephropathy

NCT01068041

Diabetic Nephropathy

COMPLETED PHASE2

Nitric Oxide (NO) Activity and Diabetic Nephropathy

NCT00136188

Diabetic Nephropathies

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is a worldwide increase in prevalence in type 2 diabetes mellitus, which is being paralleled by an increasing number of patients reaching dialysis because of diabetic nephropathy. Much of the fivefold increase in patients receiving dialysis treatment that occurred over the past two decades is attributable to type 2 diabetes and diabetic nephropathy. Diabetes is now the leading cause of end-stage renal disease (ESRD), with more than 40% of all new cases of ESRD occurring in patients with diabetes.

Benfotiamine has been shown to reduce diabetic nephropathy and retinopathy in animal experimental models. We hypothesize that benfothiamine supplementation in patients with diabetic nephropathy will ameliorate the effects of both albuminuria/proteinuria and hyperglycaemia on oxidative stress and advanced glycation end-products (AGEs) accumulation in renal tissue, and thereby decrease inflammatory responses and fibrotic responses, causing slowing down of progression to ESRD as a consequence.

Intervention:

The intervention duration is 12 weeks for each group.

* Group A: Benfotiamine (300 mg) 3x 1 film coated tablet daily (900 mg daily dose benfotiamine)
* Group B: Placebo 3x 1 film coated tablet daily

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Nephropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Group Type ACTIVE_COMPARATOR

Benfotiamine

Intervention Type DRUG

3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.

B

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

3x 1 film coated tablet daily. Duration: 12 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Benfotiamine

3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.

Intervention Type DRUG

Placebo

3x 1 film coated tablet daily. Duration: 12 weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Milgamma® mono 300, Wörwag Pharma GmbH & Co. KG A11DA05 Placebo, Wörwag Pharma GmbH & Co. KG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes mellitus
* Patients are on treatment with angiotensin converting enzyme inhibitors (ACEi) and/or angiotensin II antagonists (AIIA) in an unchanged dose for at least 3 months
* Active diabetic nephropathy as indicated by presence of microalbuminuria (15-300 mg/24 h urine) in at least two samples within 2-6 weeks in advance of inclusion in the trial
* HbA1c \< 8.5%, a higher HbA1c \< 9.5% is acceptable if the treating physician and the patient have accepted that striving for lower values is an unreachable goal (patients with high HbA1c values are the ones that one would expect to be benefit most from treatment with benfotiamine)
* eGFR (estimated by MDRD formula) \> 30 ml/min
* Males and postmenopausal females
* Written informed consent

* Severe hypoglycemia during the last 3 months, needing help from another person
* Severe hepatopathy (laboratory values about three times higher than normal
* Endocrine disorders, e.g. hyper/hypothyroidism
* Blood pressure \> 160/90 mmHg
* Severe cardiac function disturbances and severe heart rhythm disturbances
* Neoplasm's (excluding history of treated skin cancer of the type basal cell carcinoma BCC or squamous cell carcinoma SCC)
* Severe general diseases or mental disorders making the participation in the study impossible
* Drug abuse
* Female patients during pregnancy and lactation period and female patients with active menses during the past year
* Hypersensitivity to benfotiamine
* HbA1c \> 9.5%
* Use of thiamine containing supplements during the last 3 months
* Participation in another study within one month before joining the benfotiamine study